163 related articles for article (PubMed ID: 19597027)
21. Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials.
Dilli Babu A; Singh S; Thota A; Duhan S; Sainatham C; Gill H; Raghavakurup L; Tantry U; Bliden K; Gurbel P
Int J Cardiol Heart Vasc; 2024 Jun; 52():101415. PubMed ID: 38715853
[TBL] [Abstract][Full Text] [Related]
22. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
She X; Yin D; Guo Q; Tang Y; Wang S; Wang X
Sci Rep; 2024 Mar; 14(1):5592. PubMed ID: 38454105
[TBL] [Abstract][Full Text] [Related]
23. Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study.
Dicitore A; Gaudenzi G; Carra S; Cantone MC; Oldani M; Saronni D; Borghi MO; Grotteschi J; Persani L; Vitale G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001635
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the role of a four-gene signature based on EMT in the prognosis, immunity, and treatment of lung squamous cell carcinoma.
Li F; Wang H; Wang C; Li Y; Song JY; Fan KY; Li C; Ma QL; Yu Q; Zhang SP
Aging (Albany NY); 2023 Jul; 15(14):6865-6893. PubMed ID: 37462692
[TBL] [Abstract][Full Text] [Related]
25. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
26. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen HM; Guz-Montgomery K; Saha D
Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
[TBL] [Abstract][Full Text] [Related]
28. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
Liu L; Zhang Y; Wei J; Chen Z; Yu J
J Cancer; 2019; 10(4):799-809. PubMed ID: 30854085
[No Abstract] [Full Text] [Related]
29. An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance.
Xu S; Ware KE; Ding Y; Kim SY; Sheth MU; Rao S; Chan W; Armstrong AJ; Eward WC; Jolly MK; Somarelli JA
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30736412
[TBL] [Abstract][Full Text] [Related]
30. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI; Fox E; Turpin BK; Goldstein SL; Liu X; Minard CG; Kudgus RA; Reid JM; Berg SL; Weigel BJ
Cancer; 2018 Dec; 124(23):4548-4555. PubMed ID: 30394521
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft.
Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
33. Prognostic and Predictive Factors for Renal Cell Carcinoma.
Suárez C; Campayo M; Bastús R; Castillo S; Etxanitz O; Guix M; Sala N; Gallardo E
Target Oncol; 2018 Jun; 13(3):309-331. PubMed ID: 29569164
[TBL] [Abstract][Full Text] [Related]
34. Newly developed anti-angiogenic therapy in non-small cell lung cancer.
Qu J; Zhang Y; Chen X; Yang H; Zhou C; Yang N
Oncotarget; 2018 Feb; 9(11):10147-10163. PubMed ID: 29515799
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Montella L; Palmieri G; Addeo R; Del Prete S
World J Gastroenterol; 2016 Jul; 22(27):6114-26. PubMed ID: 27468204
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers for tyrosine kinase inhibitors in renal cell cancer.
Coupe N; Harrison M; Chua W; de Souza P
Transl Androl Urol; 2012 Dec; 1(4):216-22. PubMed ID: 26816714
[No Abstract] [Full Text] [Related]
37. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL; Zhao L; Belile E; Sacco AG; Chepeha DB; Dobrosotskaya I; Spector M; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey T; Worden FP
Invest New Drugs; 2015 Dec; 33(6):1248-56. PubMed ID: 26453566
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Devery AM; Wadekar R; Bokobza SM; Weber AM; Jiang Y; Ryan AJ
Int J Oncol; 2015 Sep; 47(3):849-56. PubMed ID: 26179332
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
[TBL] [Abstract][Full Text] [Related]
40. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
